Compare Cincinnati Financial Corporation (CINF) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Citius Pharmaceuticals Inc — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.68B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Cincinnati Financial Corporation is far larger — about 1424.5× Citius Pharmaceuticals Inc's market cap, and Cincinnati Financial Corporation pays a 2.16% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CINF | CTXR | |
|---|---|---|
Market Cap | $26.68B | $18.73M |
Sector | Financials | Health |
52-Week High | $192.03 | $1.82 |
52-Week Low | $149.79 | $0.48 |
Enterprise Value | $25.80B | $14.95M |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $176.86, down 1.22% on the day, with a bearish technical signal but strong fundamentals including a P/E of 8.35 and ROE of 21.48%. Recent Q2 2026 earnings missed estimates at $1.43 per share versus $1.84 expected, though revenue grew year-over-year. The company maintains robust cash flow, with 2025 operating cash flow at $3.11 billion, and a consistent dividend history, including a recent $0.94 payout.
Outlook is mixed: valuation appears attractive with analyst consensus price target of $195, but near-term headwinds include catastrophe losses and commercial lines weakness. Long-term growth is supported by premium expansion and investment income, though investors face risks from underwriting volatility and economic sensitivity.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
